TYK MEDICINES-B (02410) saw its shares rise more than 7%. As of the time of writing, the stock was up 7.07%, trading at HKD 10.9 with a turnover of HKD 30.54 million.

On March 31, TYK MEDICINES-B released its annual results for the period ending December 31, 2025. The company reported R&D costs of approximately RMB 244 million, a year-on-year increase of 3.7%. Other income and gains amounted to RMB 37.609 million, up 23.14% compared to the previous year. During the reporting period, other income and gains primarily included government grants related to revenue, government grants associated with interest-free financing, and gains from the sale of a subsidiary.

Notably, TYK MEDICINES-B announced that it will present research progress and findings for five innovative drug candidates at the poster session of the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased are TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five are self-developed small-molecule anti-tumor innovative drug candidates.

The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22 in San Diego, USA. The company's posters will be presented on April 19, April 20, and April 21.